Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix

International Journal of Gynecological Cancer

Volumn 13, Issue 4, 2003, Pages 497-504

  Eralp, Yesim ^a   Saip, P ^a   Sakar, B ^a   Kucucuk, S ^a   Aydiner, A ^a   Dincer, M ^a   Aslay, I ^a   Topuz, E ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Prognosis; Recurrent cervical carcinoma; Survival

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; DISEASE FREE INTERVAL; DRUG RESPONSE; FATAL EVENT; FATALITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION FIELD; RECURRENT CANCER; THROMBOCYTOPENIA; TIME; UTERINE CERVIX CARCINOMA;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 1242294370     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13325.x     Document Type: Article

References (20)

1. Thigpen JT, Vance R, Puneky L et al. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol, 1995;2 (Suppl. 3):16-24.
2. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med 1996;334:1030-8.
3. Murad AM, Triginelli SA, Ribalta JCL. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994;12:55-9.
4. Sugiyama T, Yakushiji M, Noda K et al. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 2000;58:31-7.
5. Burnett AF, Roman LD, Garcia AA, Muderspach LI, Brader KR, Morrow CP. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2000;76:63-6.
6. Papadimitriou CA, Sarris K, Moulopoulos LA, Fountzilas G, Anagnostopoulos A. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 1999, 17:761-6.
7. Alberts DS, Kronmal R, Baker LH et al. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix. A Southwest Oncology Group Study. J Clin Oncol 1987;5:1791-5.
8. Omura GA, Blessing JA, Vaccarello L et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 1997;15:165-71.
9. Vermorken JB, Zanetta G, De Oliveira CF et al. Randomized phase III trial of bleomycin, vindesine, mitomycin-C and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix. An EORTC Gynecological Cancer Cooperative Group Study. Ann Oncol 2001;12:967-74.
10. Jobson VW, Muss HB, Thigpen JT, Homesley HD, Bundy B. Chemotherapy of advanced squamous carcinoma of the cervix: a phase I-II study of high-dose cisplatin and cyclophosphamide. A pilot study of the Gynecologic Oncology Group. Am J Clin Oncol 1984;7:341-5.
11. Lele SB, Piver MS, Barlow JJ. Cyclophosphamide, adriamycin, and platinum chemotherapy in treatment of advanced and recurrent cervical carcinoma. Gynecol Oncol 1983;16:15-8.
12. Hoffman MS, Roberts WS, Bryson SC, Kavanagh JJ Jr, Cavanagh D, Lyman GH. Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide. Gynecol Oncol 1988;29:32-6.
13. Fanning J, Ladd C, Hilgers RD. Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. Gynecol Oncol 1995;56:235-8.
14. Zanetta G, Fei F, Parma G, Balestrino M, Lissoni A, Gabriele A, Mangioni C. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 1999;10:1171-4.
15. Pignata S, Silvestro G, Ferrari E et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol 1999;17:756-60.
16. Brader KR, Morris M, Levenback C, Levy L, Lucas KR, Gershenson DM. Chemotherapy for cervical carcinoma. factors determining response and implications for clinical trial design. J Clin Oncol 1998;16:1879-84.
17. Zanetta G, Torri W, Bocciolone L, Lucchini V, Mangioni C. Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: a multivariate analysis. Gynecol Oncol 1995;58:58-63.
18. Hempling RE, Eltabbakh GH, Piver MS, Recio FO, O'Neill CP. The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide does not improve survival in advanced or recurrent cervical carcinoma. Am J Clin Oncol 1997;20:315-8.
19. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1999;17:2676-80.
20. Zanetta G, Fei F, Mangioni C. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin Oncol 2000;27(Suppl. 1):23-7.